BBNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Beta Bionics Inc (BBNX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows promising revenue growth and potential in the diabetes market, the recent price drop, mixed analyst ratings, and lack of strong proprietary trading signals suggest waiting for more clarity post-earnings or a better entry point.
The MACD is positive and expanding, indicating bullish momentum, but RSI is neutral at 65.572. Moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 12.618), with support at 10.891. The stock's recent 6.45% drop in regular trading suggests bearish sentiment.
Strong revenue growth of 57% YoY in Q4 2025, driven by a 295% surge in pharmacy channel sales.
Analysts highlight the company's differentiated technology and potential to disrupt the insulin pump market.
Positive sentiment ahead of Q1 2026 earnings, with revenue expected to grow 57.3% YoY.
Significant regular market price drop of 6.45%, indicating bearish sentiment.
Lowered price targets from multiple analysts due to operational risks and slower patient start momentum.
Net income and EPS have declined YoY, reflecting profitability challenges.
In Q4 2025, revenue increased by 57.15% YoY to $32.12M, driven by strong pharmacy channel sales. However, net income dropped by 25.64% YoY to -$13.47M, and EPS declined by 28.57% YoY to -0.3. Gross margin improved slightly to 58.98%.
Analysts are mixed on BBNX. Most maintain a Buy rating, but price targets have been lowered significantly, reflecting concerns about operational risks and slower growth momentum. The current price is below even the lowest price targets, indicating potential upside if the company executes well.
